Hyaluronate-Peanut Agglutinin Conjugates for Target-Specific Bioimaging of Colon Cancer

Bioconjug Chem. 2017 May 17;28(5):1434-1442. doi: 10.1021/acs.bioconjchem.7b00126. Epub 2017 Apr 5.

Abstract

Colon cancer is one of the most common death-related cancers in the world. For treating colon cancer, it is crucial to detect and remove malignant lesions early. Here, we developed hyaluronate (HA)-peanut agglutinin (PNA) conjugates for the bioimaging of colon cancer. The HA-PNA conjugates were successfully synthesized by the coupling reaction between aldehyde-modified HA and the N-terminal amine group of PNA. For diagnostic imaging, rhodamine B (RhoB) was chemically conjugated onto PNA in HA-PNA conjugates. After intraluminal injection of HA-PNA-RhoB conjugates into tumor-bearing mice, small-sized colon cancers could be effectively visualized by ex vivo imaging with an in vivo imaging system (IVIS) and a two-photon microscope. With these results taken together, we could confirm the feasibility of HA-PNA-RhoB conjugates as a bioimaging agent for detecting colon cancers.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Cell Proliferation / drug effects
  • Colonic Neoplasms / chemically induced
  • Colonic Neoplasms / metabolism
  • Colonic Neoplasms / pathology*
  • Dextran Sulfate / toxicity
  • Humans
  • Hyaluronic Acid / chemistry*
  • Hyaluronic Acid / pharmacokinetics
  • Male
  • Mice
  • Mice, Inbred C57BL
  • Microscopy, Fluorescence / methods*
  • Peanut Agglutinin / chemistry*
  • Peanut Agglutinin / pharmacokinetics
  • Tissue Distribution
  • Tumor Cells, Cultured
  • Xenograft Model Antitumor Assays

Substances

  • Peanut Agglutinin
  • Hyaluronic Acid
  • Dextran Sulfate